New Drug for Bladder Cancer: Atezolizumab - National Cancer Institute

Atezolizumab - National Cancer Institute

Atezolizumab

• 
• 
• 
• 
• 
• 
• 

(A-teh-zoh-LIZ-yoo-mab)

This page contains brief information about atezolizumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Tecentriq

FDA Approved

Yes

FDA Approval for Atezolizumab

Use in Cancer

Atezolizumab is approved to treat:

• Urothelial carcinoma (a type of bladder cancer) that is locally advanced or hasmetastasized (spread to other parts of the body). It is used in patients whose disease has gotten worse during or after treatment with platinumchemotherapy.

Atezolizumab is also being studied in the treatment of other types of cancer.

More About Atezolizumab

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trials Accepting Patients

Find Clinical Trials for Atezolizumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.

• Posted: May 20, 2016
• Updated: May 20, 2016

Atezolizumab - National Cancer Institute